Having discovered the palmitoylation motif of APLNR, we created a short substrate sequence to competitively inhibit the palmitoylation of endogenous APLNR. This aggressive peptide, which targets the APLNR palmitoylation web page together with morphine, can inhibit the event of NCP, such as pain incidence, microglial activation, and inflammatory factor https://deanygysf.dreamyblogs.com/27264020/getting-my-block-pain-receptors-with-proleviate-to-work